AUSTIN,
Texas, Nov. 15, 2022 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare metabolic diseases,
today announced that Linda Neuman,
M.D., M.B.A. has been appointed chief medical officer. Dr. Neuman's
appointment is an internal promotion from her previous role as
Aeglea's senior vice president of clinical development.
"Linda brings significant medical expertise and drug development
experience to the Aeglea leadership team and will play an important
role in helping to guide the development strategy for pegtarviliase
and the rest of our portfolio," said Jim
Kastenmayer, Ph. D., J.D., interim chief executive officer
and general counsel of Aeglea. "Linda has proven that she has the
creative and flexible leadership required to navigate the
complexities of drug development and has made a significant impact
on our medical strategy since joining our team. I am excited to
continue working closely with Linda as a valued member of our
executive leadership team."
Prior to joining Aeglea in 2021, Dr. Neuman served as vice
president, clinical development at Catalyst Biosciences where she
led the clinical development of their late-stage development
program for a novel hemophilia treatment. Before Catalyst, she
served as the interim chief medical officer at Adverum
Biotechnologies, where she directed the early phase development for
three gene therapy programs, including two Investigational New Drug
Applications (IND) in rare disease and ophthalmology indications.
She previously worked at Sunesis Pharmaceuticals where she led the
filing of an Investigational New Drug (IND) application and
initiated a Phase 1b/2 clinical study
and Puma Biotechnology, Inc., where she contributed to the
successful New Drug Application (NDA) and Market Authorization
Application (MAA) for neratininb. She began her career as an
internist and practiced medicine for 10 years prior to joining
industry. Dr. Neuman earned an M.D. from Southern Illinois University School of Medicine, a
B.S. in biology from Southern Illinois
University, and an M.B.A from Indiana
Wesleyan University.
About Aeglea
BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare metabolic diseases with limited treatment options.
Aeglea is investigating pegtarviliase in an ongoing Phase 1/2
clinical trial for the treatment of Classical Homocystinuria.
Pegtarviliase has been granted Rare Pediatric Disease Designation.
Aeglea's other clinical program, pegzilarginase, achieved the
primary endpoint of arginine reduction in the PEACE Phase 3
clinical trial and has received both Rare Pediatric Disease and
Breakthrough Therapy Designations. The Marketing Authorization
Application for pegzilarginase is currently under review with the
European Medicines Agency. Aeglea has an active discovery platform
focused on engineering small changes in human enzymes to have a big
impact on the lives of patients and their families. For more
information, please visit http://aeglea.com.
Safe Harbor / Forward Looking
Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, statements we
make regarding the timing of announcements and updates relating to
our clinical trials and related data, including the clinical data
for our Phase 1/2 trial of pegtarviliase in Classical
Homocystinuria, the timing and success of our clinical trials and
related data, the timing and expectations for regulatory
submissions and approvals, including the MAA for pegzilarginase in
Europe, our ability to obtain
regulatory approval for, and commercialize, pegzilarginase,
recognize milestone and royalty payments from our agreement with
Immedica, our ability to enroll patients into our clinical trials,
the expected impact of the COVID-19 pandemic on our operations and
clinical trials, success in our collaborations, the length of time
that we believe our existing cash resources will fund operations,
the potential addressable markets of our product candidates and the
potential therapeutic benefits and economic value of our lead
product candidate or other product candidates. Further information
on potential risk factors that could affect our business and its
financial results are detailed in our most recent Quarterly Report
on Form 10-Q for the quarter ended September
30, 2022 filed with the Securities and Exchange Commission
(SEC), and our other reports as filed with the SEC. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-appoints-linda-neuman-md-mba-to-chief-medical-officer-301679208.html
SOURCE Aeglea BioTherapeutics, Inc.